Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017636 (glioblastoma)
 18,345 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nuclear and cell density features have been measured in 22 cases of glioblastoma divided into two groups according to their survival periods, i.e. less than 12 months or more than 12. The results have demonstrated that the logarithmic transformation of the following features show up statistically significant differences (p less than 0.05): mean of the logarithm of nuclear area, standard deviation of the logarithm of perimeter and standard deviation of the logarithm of the roundness factor. The standard deviation of the roundness factor has been shown to be another parameter with statistically significant differences between the two groups. Forward stepwise discriminant analysis was adopted in order to identify the quantitative features which contributed most significantly to discriminating between the two groups. The results suggested a combination of two features, i.e. the standard deviation of the logarithm of the roundness factor and the mean of the logarithm of the roundness factor. The comparison between actual and predicted categories showed 68.18% agreement: 7 out of 22 cases were allocated incorrectly by the computer. However, when a classification probability threshold was adopted, the 7 incorrectly allocated cases assumed an "intermediate" position between the two groups, in agreement with their survival.
Neurochirurgia (Stuttg) 1989 Sep
PMID:Malignant glial tumours: prognostic value of quantitative microscopy. 279 57

Three-tiered system dividing supratentorial astrocytic neoplasms into the astrocytoma, anaplastic (malignant) astrocytoma and the glioblastoma multiforme has been widely used. However, the pathology of anaplastic astrocytoma is defined in different ways according to different classifications. A total of 42 biopsy specimens from 35 cases diagnosed as anaplastic astrocytoma were reviewed pathologically and their features were correlated with a follow-up clinical study to discuss the prognostic usefulness of the subdivision of anaplastic astrocytoma. In WHO classification, anaplastic astrocytoma is defined as "astrocytoma containing areas of anaplasia". Follow-up study of 7 cases with the histology as such revealed that 5 cases had survived more than one year and seven months. The other 28 cases showed a varied histology and were subclassified into an astrocytoma in which moderately anaplastic cells are found throughout the tumor, an astrocytoma formed by anaplastic fusiform cells, an astrocytoma composed of predominantly rounded anaplastic cells, and a pleomorphic astrocytoma with or without intracytoplasmic hyaline inclusions. A follow-up study of cases with these types of astrocytoma disclosed death in 15 cases within one year and 7 months following the first surgery and that three cases displayed typical histological features of glioblastoma at autopsy. It is considered that there would be a considerable overlap between the group of anaplastic astrocytoma and that of glioblastoma, if we use the term "anaplastic astrocytoma" in a broader category.
Gan No Rinsho 1989 Sep
PMID:[Problems entailed in the definition and pathology of anaplastic astrocytoma]. 281 Jul 69

From the data in vol. 6 of Brain Tumor Registry in Japan, there were mainly analyzed the survival rates of malignant astrocytoma and glioblastoma patients related to extent of surgical removal and postoperative radiation. Total removal of the supratentorial astrocytoma in brain revealed 75.9% in 5-year survival rate, whereas supratentorial malignant astrocytomas and glioblastomas, 43.7% and 20.9% in 5-year survival rates, respectively. Survival rates related to combination of operation and radiation therapy for the glioblastoma and malignant astrocytoma patients were analyzed according to the mode of operation. For glioblastomas, patients treated with biopsy and post-operative radiation therapy indicated higher survival rate of 6.3% in 5-year survival than the patients with biopsy and no radiation, 3.0% of 5-year survival rates (P less than 0.01 by Chi-square test). On the other hand, patients treated with 95%-100% removal by operation with or without radiation therapy showed 67.2% (with), 32.1% (without) in 1 year survival; 37.2%, 23.1% in 2 year survival; 27.1%, 20.0% in 3 year survival; 22.5%, 20.2% in 4 year survival and 20.4% and 19.4% in 5-year survival rates, respectively (P less than 0.05 by Chi-square test). Tentative TNM classification proposed by Japan to UICC was also discussed briefly.
Gan No Rinsho 1989 Sep
PMID:[Analysis of therapeutic factors related to survival rate for malignant glioma patients--report from Brain Tumor Registry in Japan, Vol. 6, 1987]. 281 Jul 71

One hundred one patients with glioblastoma were studied to evaluate the effect of the extent of surgical resection on the length and quality of life. Extensive removal of tumor was performed for 45 patients, while the remaining 56 patients underwent partial removal or biopsy of tumor. The median time to tumor progression and the median survival in the former patients were 18.0 months and 23.0 months, respectively, and, in the latter patients, 6.0 months and 10.0 months, respectively. More than 80% of Karnofsky rating was observed in 69% of the former patients. Extensive removal of glioblastoma would be associated with longer and better survival when compared to partial removal.
Gan No Rinsho 1989 Sep
PMID:[Surgical treatment on survival and quality of life in patients with supratentorial glioblastoma:]. 281 Jul 72

For the past twenty years, 85 adult patients with cerebral glioblastoma were treated with postoperative radiation therapy (RT). Hypofractionated RT (5 Gy twice a week) was performed in 31 patients. The survival rate of the hypofractionated RT was superior to the conventionally fractionated RT, especially in the patients involved mainly in the frontal lobe. In the hypofractionation group, misonidazole proved of benefit to the survival. In future, hyperfractionation of RT seems reasonable to be explored for improving CNS tolerance.
Gan No Rinsho 1989 Sep
PMID:[Radiation therapy of adult cerebral glioblastoma:]. 281 Jul 73

A combination of multiple primary neoplasm (MPN) with glioblastoma and cancer of other organs is extremely rare but might be spurred up in the field of neurosurgery because of increasing number of cured patients from cancer or malignant brain tumor. Four such cases are presented. Two of them are of heterochronous occurrence of tumors. One has survived for 17 years after treating four malignancies: uterus, stomach, breast cancer and glioblastoma multiforme in this order and free of brain tumor for 4 years. The other has survived 18 years after three malignancies: uterus, stomach cancer and glioblastoma but is in morbid neurological state for a year. A case of synchronous primary tumors is a combination with glioblastoma and maxillary cancer and the patient died of brain tumor after 4 years and two months. The other case is an old man with glioblastoma and stomach cancer but died of severe general and neurological condition for three months before treatment was started. The pathogenesis of MPN is unknown. Regarding intrinsic factors, heredity, age, genetic or immunological state have been proposed for possible mechanism of the synchronous occurrence of MPN. While extrinsic factors such as environmental changes due to irradiation or chemical exposure to host might also be important for heterochronous MPN. Discussions based on these cases and literature were also made on the biological nature and clinical characteristics of MPN malignant brain tumor combined with cancer of other organs.
No Shinkei Geka 1987 Sep
PMID:[Multiple primary neoplasm--glioblastoma combined with cancer of other organs]. 282 47

The growth inhibitory effects of the combination of beta-interferon (beta-IFN) and conventional anticancer drugs such as adriamycin (ADM) and ACNU were evaluated in nude mice receiving subcutaneous transplants of human glioblastoma. Next, the anticancer and radiation sensitizing effects of beta-IFN on human glioblastoma was also evaluated in nude mice model. After three weeks of combined treatment, tumour reduction rates (treated/control values) were evaluated by the Battelle's method. In conclusion, the growth inhibitory effect of IFN was most enhanced when IFN was administered following radiotherapy. Furthermore, the combined effect was enhanced in proportion to the dose of radiation.
Neurol Res 1986 Sep
PMID:Interactions of human fibroblast interferon with chemotherapeutic agents and radiation against human gliomas in nude mice. 287 8

The somatomedins (IGF-1/IGF-2) are a family of growth-promoting hormones which have been identified in the human central nervous system where their specific receptors are distributed. The present study identified somatomedin receptors in glioblastoma and compared them with those found in normal brain. A significant enhancement in the binding of 125I-IGF-2 but not 125I-IGF-1 to glioblastoma membranes was found. A fourfold increase in IGF-2 receptor concentration was observed. These findings indicate enhanced expression of the IGF-2 receptor in glioblastoma.
Cancer Lett 1986 Sep
PMID:Enhancement of insulin-like growth factor 2 receptors in glioblastoma. 294 33

A receptor for the adhesive basement membrane protein, laminin, was isolated from human glioblastoma cells by affinity chromatography on laminin. This receptor has a heterodimeric structure similar to that of receptors for other extracellular matrix proteins such as fibronectin and vitronectin. Incorporation of the laminin receptor into liposomal membranes makes it possible for liposomes to attach to surfaces coated with laminin. The receptor liposomes also attached to some extent to surfaces coated with fibronectin, but not with other matrix proteins. These properties identify the laminin receptor as a member of the integrin family of cell adhesion receptors.
Science 1988 Sep 02
PMID:The human laminin receptor is a member of the integrin family of cell adhesion receptors. 297 Jun 71

The effects of dipyridamole on tumor cell function were examined in cultures of two lines of human origin, the SKNMC neuroblastoma line that activates platelets by a mechanism which is dependent on the release of adenosine 5'-diphosphate and the U87MG glioblastoma line that induces platelet activation by the generation of thrombin. Cells grown in the presence of dipyridamole at 1 microM showed greater than 80% inhibition of uptake of adenosine, thymidine, and uridine with both lines. At 5 microM tumor cell growth was inhibited by 70% (U87MG) and 90% (SKNMC) but without concomitant cytotoxicity as determined by clonogenic assay (50% inhibitory concentration approximately 20 microM). At 10 microM dipyridamole cyclic adenosine 3':5'-monophosphate levels increased 150% with both cell lines but no changes above baseline values were seen at 2.5 microM. The two cell lines showed different responses to being cultured in the presence of dipyridamole in terms of their ability to subsequently activate platelets. U87MG cells cultured in 10 microM dipyridamole showed a doubling of the lag time as compared with cells grown in the absence of dipyridamole but with full aggregation; with SKNMC cells the aggregation rate was reduced and cells grown in 10 microM dipyridamole showed no reversible first wave, a 5-fold increase in lag time and a 75% inhibition in total aggregation. Since therapeutic doses of dipyridamole result in plasma concentrations of approximately 3.5 microM these results suggest that potential antimetastatic effects of dipyridamole could be direct arising from inhibition of important steps in tumor cell metabolism or indirect by suppressing one or more of the mechanisms involved in the ability of tumor cells to activate platelets.
Cancer Res 1985 Sep
PMID:Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines. 299 71


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>